Somatic activating mutations in the ERBB2 (HER2) gene are present in approximately 3–5% of patients with metastatic HR‐positive breast cancer and are associated with endocrine resistance due to crosstalk between HER2 and ER signaling pathways. Here, ESR1 is linked to breast carcinoma.